Diego Aldave

Oncólogo Radioterápico #RadOnc

[ASTRO @ASTRO_org]

The #PROTEUS trial contributes important knowledge to the evolving evidence on high-risk #prostatecancer treatment options. ASTRO’s new summary document from @NehaVapiwala and @AmarUKishan is a member resource for discussions with your #multidisciplinary colleagues and patients.

https://t.co/HywTq0w7oa

[Dr. Nina Niu Sanford @NiuSanford]

Impressive daraxonrasib data.

From RT standpt, if RAS inhibition meaningfully prolongs dz control, local progression = more relevant

Future trials should test consolidative ablative RT in pts responding to darax (potentially leveraging RAS-mediated radiosens) #ASCO26 @OncoAlert

[Daniel E Spratt @DrSpratticus]

The real question is the Enzarad data, which is not a subgroup analysis like STAMPEDE.

STAMPEDE is hands down my favorite trial ever, but important to note that the M0 analysis was a subgroup analysis and not all patients even had local therapy. Some patients had PSAs in the 1000s.

Enzarad a bit more relevant where MFS and OS were not significantly improved in N0M0 patients. Just like PROTEUS MFS and OS were not improved by conventional imaging.

Given we now often get PSMA PET/CT upfront for staging, ARPIs in N0M0 patients have no proven role.

[Daniel E Spratt @DrSpratticus]

#ASCO26
The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published.

Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret!

@urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry

https://t.co/NBqs5NWXDx

Analysis of the international PROMISE registry evaluated salvage radiotherapy (SRT)☢️ in 1,410 patients with biochemical recurrence after prostatectomy, using advanced PSMA PET imaging for restaging. Over a median 5.2-year follow-up, SRT was associated with significantly improved overall survival, particularly in patients with PET-negative (miT0N0M0) disease and PSA ≤0.5 ng/mL.

Five- and seven-year survival rates were higher with SRT, supporting its role as an effective treatment strategy in selected patients with recurrent #ProstateCancer

@ProfKHerrmann @ProfHadaschik @Dr_K_Rahbar @MatthiasEiber @andrea_farolfi @lauraevangelis9 @bjartell

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Priyamvada Maitre @docpriyamvada]

🤩 Finally OUT in @JCO_ASCO!

BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy

A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas

https://t.co/B8iTgImLHr

[Shankar Siva @_ShankarSiva]

Thank you @TheLancetOncol for accepting the concurrent publication of the data…. To read more see QR code here; #ESTRO26 #radonc

[Pierre Blanchard, MD @PBlanchardMD]

Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).

Twittorial below

Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...

1/n

[Daniel E Spratt @DrSpratticus]

@PCaParker @Prof_Nick_James @UroCancer @NCCN @Uroweb @AmarUKishan @TylerSbrt @HimanshuNagarMD @seanmmcbride @ChrisSweens1 @ChadTangMD 9/n Of course we should first do no harm...

@piet_ost @_ShankarSiva @DrAndrewLoblaw

[Daniel E Spratt @DrSpratticus]

For those that couldnt make it to #AUA26, especially those at #ESTRO26, here were some of the slides for the "Pro" RT to primary in M1a disease.

@TylerSbrt @UroCancer @CaPsurvivorship @PCaParker @Prof_Nick_James @wandering_gu

[OncoAlert @OncoAlert]

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨
Five-year follow-up outcomes from JCOG1208: A single-arm confirmatory trial of IMRT alone for early-stage oropharyngeal cancer Presenter Satoaki Nakamura 🇯🇵

JCOG1208 prospectively evaluated intensity-modulated radiotherapy alone for patients with early-stage oropharyngeal cancer and favorable performance status. At five years, overall survival was 88% and local progression-free survival was 79%, with durable disease control after de-escalated treatment. These results support two-step IMRT alone as a treatment option that may reduce chemotherapy-related burden while maintaining favorable long-term outcomes.

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Abrahams Ocanto @abraocantoMD]

La @SEOR_ESP y @URONCOR publican un posicionamiento relevante sobre la prescripción por Oncólogos Radioterápicos de iPARP en cáncer de próstata avanzado.
📌 Respaldo legal
📌 Manejo multidisciplinar
El futuro de la oncología es muldisciplinar.

[ESTRO @ESTRO_RT]

We are proud to announce the results of the #ESTROElections 2026. Please join us in congratulating our newly elected leadership:
✅ President-Elect: Carmen Rubio Rodríguez
✅ Board Members: Rita Simões & Piotr Wojcieszek
🙏 Thank you to all candidates & to our members who voted.

[Tyler Seibert MD PhD @TylerSbrt]

Nice observation that RT to the primary may be preferable to intensifying systemic therapy in older patients w #ProstateCancer

@APCCC_Lugano #APCCC

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Long-term survival for patients with newly-diagnosed metastatic cancer has more than doubled ⏫in the past 40 years.

However, not all patients live longer.

https://t.co/zNg546hKcc
https://t.co/X6wTFytYPL

Work via @JCOOP_ASCO from team at @UHhospitals @CWRUSOM @MayoClinic

[JAMA Oncology @JAMAOnc]

📄 This JAMA Oncology Patient Page describes different types of common mouth problems during #cancer treatment and how to care for them. https://t.co/gxKo4tcQKr

[Piet Ost @piet_ost]

@ZilliThomas highlights the progress made with SBRT in mCRPC. The OS benefit in ARTO by @GiulioFrancoli1 is very encouraging. All trials in this setting point in the same direction: benefit on all endpoints! #APCCC26

[JAMA Oncology @JAMAOnc]

Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. https://t.co/s71OKRi7TO

[Daniel E Spratt @DrSpratticus]

#APCCC26 Jochin Walz crushes his talk and makes the strong case why waiting until imaging is positive after RP is inappropriate and non-evidence based. Early is better!

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.